Summary & Overview
Malignancy, Male Reproductive System with MCC: Inpatient Reimbursement Overview
DRG 722 addresses inpatient stays for malignancy of the male reproductive system with a Major Complication or Comorbidity, covering higher-severity cases that drive increased resource use. It matters for inpatient reimbursement because Medicare Severity Diagnosis-Related Group assignment, influenced by documented comorbidities and complications, affects hospital payment levels under Centers for Medicare & Medicaid Services rules.
DRG 722 Overview
DRG 722 covers hospital admissions for malignant neoplasms of the male reproductive system when a Major Complication or Comorbidity is present, typically including complex cases such as advanced prostate or testicular cancers with significant secondary conditions. This Diagnosis-Related Group groups patients by clinical similarity and resource use, informing Medicare inpatient payment adjustments based on severity. The presence of a Major Complication or Comorbidity increases expected resource consumption and payment relative to less severe groupings. Hospitals and coders use this DRG to align clinical documentation with appropriate Medicare Severity Diagnosis-Related Group reimbursement.
National Payment Rates
Across commercial payers the observed rate range runs roughly from $16K to $62K, with the widest spread between the lowest median-level payer and the highest observed maximum among payers. Cigna, Anthem, Blue Cross Blue Shield, and Aetna show distinct payer-level dispersion; see the table and chart below for payer-specific percentiles and distributions. The largest single-payer maximum in the dataset is $62K (Anthem) while several payers have medians clustered near $28K–$32K.